Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H30ClFN2O |
| Molecular Weight | 452.991 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N(C)C(=O)CC1(CCN(C)CC1)C2=CC=C(F)C=C2)C3=C4C=CC=CC4=CC(Cl)=C3
InChI
InChIKey=DRXBWLBZWAJIEF-IBGZPJMESA-N
InChI=1S/C27H30ClFN2O/c1-19(25-17-22(28)16-20-6-4-5-7-24(20)25)31(3)26(32)18-27(12-14-30(2)15-13-27)21-8-10-23(29)11-9-21/h4-11,16-17,19H,12-15,18H2,1-3H3/t19-/m0/s1
| Molecular Formula | C27H30ClFN2O |
| Molecular Weight | 452.991 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
GlaxoSmithKline was developing GSK-424887as a dual antagonist of the human neurokinin receptor 1 and inhibitor of the serotonin transporter. GSK 424887 participated in phase I clinical trials for the treatment of depressive disorder and anxiety disorder. However, further development of GSK 424887 apparently was discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:38:38 GMT 2025
by
admin
on
Mon Mar 31 22:38:38 GMT 2025
|
| Record UNII |
IYI99KCF2T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76958276
Created by
admin on Mon Mar 31 22:38:38 GMT 2025 , Edited by admin on Mon Mar 31 22:38:38 GMT 2025
|
PRIMARY | |||
|
300000041360
Created by
admin on Mon Mar 31 22:38:38 GMT 2025 , Edited by admin on Mon Mar 31 22:38:38 GMT 2025
|
PRIMARY | |||
|
DB12219
Created by
admin on Mon Mar 31 22:38:38 GMT 2025 , Edited by admin on Mon Mar 31 22:38:38 GMT 2025
|
PRIMARY | |||
|
IYI99KCF2T
Created by
admin on Mon Mar 31 22:38:38 GMT 2025 , Edited by admin on Mon Mar 31 22:38:38 GMT 2025
|
PRIMARY |